Medical Carbon Dioxide Boc Gases Ireland (Carbon Dioxide)

When inhaled or introduced into a body cavity, carbon dioxide raises arterial PaCO₂, which activates central chemoreceptors to increase the respiratory drive. Its high solubility and inertness also create a stable pneumoperitoneum, providing a clear operative field without reacting with tissues.

The dose and flow rate of medical carbon dioxide are determined by the prescribing clinician based on the specific procedure, patient characteristics, and monitoring parameters. No fixed regimen is provided in the product information.

Safety data for carbon dioxide in pregnancy and lactation are limited. It should only be used when clearly indicated and when the potential benefits outweigh any theoretical risks. Clinicians should evaluate each case individually.

Enquiries can be submitted on the product page at gnhindia.com by entering the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Carbon dioxide is preferred over gases such as nitrous oxide or helium because it is highly soluble, rapidly absorbed, and non‑flammable, reducing the risk of gas embolism and postoperative pain. Its physiological effects on ventilation also allow controlled respiratory stimulation when needed.

Store the gas cylinders at ambient temperature, upright, and in a well‑ventilated area away from direct sunlight, heat sources, and moisture. Ensure cylinders are secured to prevent tipping and follow all local regulations for compressed gas handling.

Medical carbon dioxide is delivered via a regulated gas delivery system. For insufflation, it is introduced through a laparoscopic insufflator or similar device. For therapeutic inhalation, it is mixed with carrier gases and administered through a calibrated breathing circuit under continuous monitoring.

The most serious risks include severe hypercapnia leading to respiratory acidosis, cardiac arrhythmias, and pulmonary edema. Continuous capnography and hemodynamic monitoring are essential to detect early signs of these complications.

Patients with uncontrolled severe chronic obstructive pulmonary disease, untreated hypercapnia, or known hypersensitivity to carbon dioxide should not receive this product. It is also contraindicated in situations where high‑flow oxygen therapy would negate its intended respiratory effects.